Medicare may be paying for more screening colonos - copies than are warranted for the prevention of colorectal cancer (CRC), according to a new study (Goodwin JS, et al. Arch Intern Med. 2011 May 9 [Epub ahead of print]). [ Read More ]
Most professional guidelines now recommend screening for hepatitis B virus (HBV) infection in essentially all patients receiving chemotherapy, but it is seldom performed and is not cost-effective in patients with solid (nonhematologic) tumors, according to studies presented at ASCO 2011.[ Read More ]
Ongoing efforts to screen asymptomatic persons for pancreatic cancer have been unsuccessful, but targeting persons at high risk for the disease appears to be clinically effective as well as cost-effective.
Researchers have combined the use of a serum biomarker, CA 19-9, and endoscopic ultrasonography to create a screening protocol for persons at risk for the malignancy on the basis of family history and age and reported their results in the July issue of Gastro - intestinal Endoscopy (Zubarik R, et al. Gastrointest Endosc. 2011;74:87-95).[ Read More ]
Dose-monitoring programs for oral chemotherapy drugs can reduce wastage and reduce the risk of serious adverse effects associated with these drugs. This translates into cost-savings for patients and for payers of >$2500 per patient, suggested researchers from Walgreens Specialty Pharmacy.
The company developed an oral chemotherapy cycle management program (CMP) that offers a “split-fill” option and close monitoring of pa - tients for adverse events. This is an optional program, and payers can elect to participate.[ Read More ]
As we move forward in the scheme of healthcare reform, we are being directed toward an integrated care model, one with high quality and economic efficiency. Recently, a model known as an accountable care organization (ACO) was introduced by the US Department of Health and Human Services in the form of a proposed rule open for public comment. [ Read More ]
Interview with Al B. Benson III, MD, FACP
Professor of Medicine and Associate Director for Clinical Investigations, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL
Q: How would you define the concept of best practices, and what makes an oncology center, such as the Northwestern University Robert H. Lurie Comprehensive Cancer Center, be among the best oncology practices in the country?[ Read More ]
Philadelphia, PA—Fragmentation in oncology care significantly influences physicians’, payers’, and patients’ understanding of how cancer therapies lead to improved quality of care. The main reason for fragmentation is the challenge in linking pharmacy and medical data in a way that generates usable information, according to Atheer A. Kaddis, PharmD, Vice President, Managed Markets, Diplomat Specialty Pharmacy. [ Read More ]
Philadelphia, PA—Implementing path - ways to sustain community oncology and offering additional nursing and care management models are recent strategies being adopted by various practices and payers to reduce the medical and pharmacy costs in cancer management and improve the quality of care. [ Read More ]
Philadelphia, PA—The new biologic therapy eribulin (Halaven) was recently approved by the US Food and Drug Administration for the treatment of patients with metastatic breast cancer. Stephen C. Malamud, MD, Attending Physician, Beth Israel Medical Center, New York City, discussed the benefits and risks associated with this new treatment option at a special session during the meeting.
[ Read More ]